Article Text

Download PDFPDF

FRI0075 Rheumatoid arthritis patients receiving glucocorticoid exhibits significant bone quality abnormalities, leading to severe bone fragility regardless of bisphosphonate treatment
  1. T Shimizu1,2,
  2. M Takahata1,
  3. H Hamano1,
  4. M Ota1,
  5. S Hiratsuka1,
  6. N Iwasaki1
  1. 1Department of Orthopeadic Surgery, Hokkaido University School of Medicine, Sapporo, Japan
  2. 2Department of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, University of California San Francisco, San Francisco, United States


Background Patients with rheumatoid arthritis (RA) receiving glucocorticoids develop particularly severe bone fragility accompanied with high risk factors for fragility fractures1,2. Although bisphosphonate is recommended for treatment of osteoporosis related RA and glucocorticoid-induced-osteoporosis3, there are more frequently fractures than expected from bone mineral density based prediction even after used bisphosphonate.

Objectives To clarify the pathological mechanisms of bone fragility of these RA patients, we investigated bone biopsy samples obtained from RA and normal postmenopausal patients.

Methods We examined 10 female postmenopausal RA patients receiving glucocorticoid and bisphosphonate therapy (RA group) and 10 age-matched female patients with postmenopausal osteoporosis (Ctl group) selected from patients who required autologous iliac bone grafts. Analyses of clinical data, bone mineral density, serum metabolic markers, bone quality and material mechanical property of biopsy sample were performed.

Results Although bone mineral density didn't show significant differences, RA group had significantly higher score of fracture risk assessment tool (FRAX), number and severity of existing vertebral fractures.

RA group exhibited significant bone quality abnormalities including deterioration of the bone microstructure, decreased calcification of the bone matrix, increased osteocyte atrophy and empty lacunae (Figure), and an impairment bone material strength properties.

Conclusions Our findings showed that RA patients receiving glucocorticoid treatment have severe bone fragility regardless of increased bone quantity by using bisphosphonate. The functional deteriorations of the osteocyte system and the abnormalities of bone quality might induce bone fragility fracture. Therefore, management of osteoporosis associated with RA should be targeted about bone quality as well as bone quantity.


  1. Kanis JA et al. J Bone Miner Res 2004.

  2. Takaha M et al. Arthritis Rheum 2012.

  3. Grossman, J.M. et al. Arthritis Care Res 2010.


Acknowledgements This project was supported in part by a Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan 25462357 (M. Takahata).

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.